Stockscreener 앱 받기
3.60
7.46%
-0.29
시간 외 거래:
3.65
0.05
+1.39%
전일 마감가:
$3.89
열려 있는:
$3.85
하루 거래량:
394.58K
Relative Volume:
2.58
시가총액:
$147.33M
수익:
$2.00M
순이익/손실:
$63.21M
주가수익비율:
2.4238
EPS:
1.4853
순현금흐름:
$-9.71M
1주 성능:
-10.89%
1개월 성능:
-9.55%
6개월 성능:
+30.91%
1년 성능:
+51.26%
1일 변동 폭
$3.58
$3.96
1주일 범위
$3.58
$4.14
52주 변동 폭
$1.975
$5.01
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.60 | 159.20M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
ORMP Should I Buy - Intellectia AI
Oramed Pharmaceuticals (ORMP) Holds Near Key Support Amid Modest DeclineDemand Zone - thelegaladvocate.com
Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy - openPR.com
Oramed Pharmaceuticals (ORMP) Drops 8.9%: Support Level Under PressureNAAIM Exposure - thelegaladvocate.com
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha
Oramed Pharmaceuticals Inc. Q1 2026 Financial Report: Key Investments, Marketable Securities, and Forward-Looking Statements - Minichart
Oramed: Q1 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary - TradingView
Oramed (NASDAQ: ORMP) swings to $38.3M Q1 profit on Alpha Tau and Scilex gains - Stock Titan
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifeward Ltd.16079622026 - SEC.gov
Oramed Pharmaceuticals (ORMP) Q4 2025 Financial OverviewIncome Pick - newser.com
Oramed Pharmaceuticals Delays Quarterly SEC Filing - TipRanks
Oramed Pharmaceuticals (NASDAQ: ORMP) notifies late Q1 2026 Form 10-Q filing - Stock Titan
About Us | Oil & Gas JournalOramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Stock Quote - FinancialContent
Oramed Pharmaceuticals (ORMP) Stock: Slides -0.74%, Support at $4.46 2026-05-15Buy Signals - newser.com
Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G - Stock Titan
Oramed Pharmaceuticals Discloses Investment at Lifeward with 49.9% Stake - TradingView
Oramed details Lifeward (LFWD) equity stake, notes and warrants - Stock Titan
Oramed (LFWD) reports 49.9% Lifeward stake, $9M notes and warrants - Stock Titan
Oramed Pharmaceuticals stock (US68403P1003): Oral drug delivery innovator for US diabetes market - AD HOC NEWS
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks - Yahoo Finance
Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30 - AD HOC NEWS
TradingKey - TradingKey
MSN Money - MSN
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
ORMP (Oramed Pharmaceuticals) falls 2.84% after releasing Q4 2025 earnings with no prior analyst consensus estimates.Current Ratio - Xã Thanh Hà
ORMP (Oramed Pharmaceuticals Inc.) rises 0.53 percent following release of its 2025 fourth quarter earnings results.Debt/Equity - Xã Thanh Hà
Oramed Pharmaceuticals (ORMP) Stock Rally Stalls (+1.05%) 2026-04-16Shared Momentum Picks - Xã Vĩnh Công
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors - Yahoo Finance
Evolus and Oramed Pharmaceuticals Compared - National Today
Setup Watch: Is Oramed Pharmaceuticals Inc stock technically oversold2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Sell Signal: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Overview Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fund Flows: Can Oramed Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Technical Analysis: Will Oramed Pharmaceuticals Inc face regulatory challenges2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Lifeward scoops US$20M after completing Oratech Pharma takeover - Mugglehead Investment Magazine
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ORMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Oramed Pharmaceuticals stock: Oral insulin pioneer or high-risk bet? - AD HOC NEWS
INO Stock Analysis: Inovio Pharmaceuticals Inc. plunges 35% to $1.13 biotech support level - Xã Thanh Hà
ORMP Q4 Earnings: Beats Estimates by $1.16 - newser.com
Oramed Completes Oratech Sale and Strategic Lifeward Financing - The Globe and Mail
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.89%
자본화:
|
볼륨(24시간):